Essa Pharma INC Schedule 13D activist filings

ESSA Pharma Inc. was acquired by Xeno Acquisition Corp. on October 9, 2025, leading to reporting persons ceasing beneficial ownership.

ESSA Pharma Inc. and major shareholder BVF have agreed to waive a beneficial ownership limitation, allowing BVF to fully exercise its common share purchase warrants.

Soleus Capital Master Fund, L.P. has increased its beneficial ownership in ESSA Pharma, Inc. to 9.8% of outstanding common stock after unwinding a cash-settled swap and acquiring 2.1 million shares.

BML Investment Partners, L.P., holding a 9.5% stake in ESSA Pharma Inc., has filed a Schedule 13D advocating for the company's liquidation or sale to return capital to shareholders.

Soleus Capital Master Fund and its affiliates have filed an Amendment No. 1 to Schedule 13D, disclosing a 5.1% beneficial ownership stake in ESSA Pharma, Inc., alongside substantial economic exposure through cash-settled swap transactions.

Soleus Capital, a significant shareholder in ESSA Pharma, Inc., has filed a Schedule 13D to advocate for the company to wind down operations and distribute its cash to shareholders, citing the current share price being significantly below its cash per share.

A group of investment funds led by Biotechnology Value Fund L.P. has disclosed a significant 19.7% beneficial ownership stake in ESSA Pharma Inc., stating the shares were acquired due to their belief in the company's undervaluation and attractive investment opportunity.